• There are no suggestions because the search field is empty.

Careers    Developers    Support     日本語

Multiple Myeloma 
Trial Solutions

Enhancing study success with advanced clinical research technologies and expert solutions for Multiple Myeloma trials.

DOWNLOAD BROCHURE GET IN TOUCH

Effective solutions for advancing Multiple Myeloma research

Clinical trials are critically important in the development of new multiple myeloma therapies and contribute greatly to obtaining a better understanding of this complex, dynamic disease. Signant Health applies decades of clinical experience and deep expertise with multiple myeloma, as well as innovative clinical trial technologies within our Signant SmartSignals suite, to optimize the quality and reliability of clinical data generated, helping teams identify new therapies sooner.

MM-1

Why Signant Health

  • Generate High-Quality Evidence & Drive New Labeling Claims
  • Empower Trials with Early-Phase Tolerability Evidence
  • Simplify the Management of Complex Trial Designs
  • Increase Patient Comprehension & Ease Burdens for Sites & Patients
  • Generate High-Quality Evidence & Drive New Labeling Claims

    Generate High-Quality Evidence & Drive New Labeling Claims 

    Signant's scientists implement a patient-reported outcomes (PRO) strategy aligned with FDA guidance to meet regulatory and HTA needs. Our solutions help sponsors collect precise measures with optimal frequency to generate informative data for decision-making. Designed with patients in mind, our approach ensures low burden while delivering high-quality data to support regulatory decisions and medication labeling claims.

  • Empower Trials with Early-Phase Tolerability Evidence

    Empower Trials with Early-Phase Tolerability Evidence 

    Patient-reported outcome measures (PROMs) are underutilized in early-phase trials but are crucial for assessing dose-tolerability and selecting effective doses for later phases. Signant's innovative ePRO solutions simplify the complex task of collecting tolerability data in early-phase studies. By integrating PROMs, we help researchers make informed decisions and optimize oncology drug development.  
     

  • Simplify the Management of Complex Trial Designs

    Simplify the Management of Complex Trial Designs 

    Oncology trials present unique challenges in randomization and ensuring medication availability due to complex study designs and treatment-related factors. Signant Health offers a flexible RTSM solution for accurate randomization and a reliable medication supply chain management system that handles variable dosing regimens and treatment interruptions. Partner with Signant Health to confidently navigate oncology trial complexities and ensure successful protocol implementation. 
     
     

  • Increase Patient Comprehension & Ease Burdens for Sites & Patients

    Increase Patient Comprehension & Ease Burdens for Sites & Patients

    Our patient-focused engagement solutions simplify clinical trial participation for patients and sites. We can help your patients complete PROs at home, use eConsent for more focused in-clinic visits, and conduct routine follow-ups via telemedicine when appropriate. This approach streamlines the trial process, making it more accessible and accommodating for oncology patients. 

Comprehensive Oncology experience

0

STUDIES

0

PATIENTS

0

COUNTRIES

0

SITES

Explore our Multiple Myeloma trial resources
SOLUTION BROCHURE

Multiple Myeloma Trial Solutions Overview


GET INSIGHTS
VIDEO

Multiple Myeloma Trial Solutions


WATCH [2 MIN]
SOLUTION

Oncology Clinical Trials


 
LEARN MORE

eClinical solutions for Multiple Myeloma trials

Ready to learn more?

Discover how Signant can support your current or upcoming multiple myeloma trials. 

 

DOWNLOAD BROCHURE GET STARTED